SuperworthRapport Therapeutics market cap RAPP
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $1.2B
- Highest close in our data
- $2.3B
- Aug 2026
Rapport Therapeutics is worth $1.2B at the close on Oct 23, 2026, at $25.93 a share.
That is up 31% over the last year.
Its highest close in our data was $2.3B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.2B | $1.2B | $2.3B | −14% |
| 2025 | $1.4B | $301.8M | $1.5B | +107% |
| 2024 | $696M | $660.9M | $976.2M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Rapport Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| RAPPRapport Therapeutics | $1.2B |
| OMEROmeros | $1.2B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.5B |
| PAHCPhibro Animal Health | $1.6B |
| ANIPANI Pharmaceuticals | $1.7B |
| ABUSArbutus Biopharma | $831M |
| COLLCollegium Pharmaceutical | $747.5M |
| HRMYHarmony Biosciences | $2.1B |
| PBHPrestige Consumer Healthcare | $2.3B |
| Peer median | $1.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Rapport Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.